Human medicines European public assessment report (EPAR): Vyepti, eptinezumab, Date of authorisation: 24/01/2022, Revision: 10, Status: Authorised

Vyepti (Eptinezumab) for Migraine Prevention: An Evidence Summary What is established Vyepti is a medicine authorised in the European Union since January 2022 for the preventive treatment of migraine in adults who experience at least 4 migraine days per month. The active ingredient, eptinezumab, is a monoclonal antibody designed to block calcitonin…

Human medicines European public assessment report (EPAR): mResvia, respiratory syncytial virus mRNA vaccine, Date of authorisation: 22/08/2024, Revision: 13, Status: Authorised

What is established On August 22, 2024, the European Medicines Agency (EMA) authorised mResvia, a messenger RNA (mRNA) vaccine designed to prevent respiratory syncytial virus (RSV) infections. RSV is a common cause of respiratory tract infections, particularly in young children and older adults, and can lead to severe illness in vulnerable populations.…

Human medicines European public assessment report (EPAR): Leflunomide ratiopharm, leflunomide, Date of authorisation: 28/11/2010, Revision: 22, Status: Authorised

Evidence Dossier: Leflunomide ratiopharm – European Medicines Agency Assessment What is established Leflunomide ratiopharm is a generic pharmaceutical medicine authorized for use within the European Union, containing the active substance leflunomide. It is used under prescription, primarily for the treatment of adults with active rheumatoid arthritis and active psoriatic arthritis, both autoimmune…

European SARS-CoV-2 and influenza virus Bioinformatics External Quality Assessment (ESIB-EQA), 2025

European SARS-CoV-2 and Influenza Virus Bioinformatics External Quality Assessment (ESIB-EQA), 2025 This article examines the 2025 report from the European Centre for Disease Prevention and Control (ECDC) on the European SARS-CoV-2 and influenza virus Bioinformatics External Quality Assessment (ESIB-EQA). The assessment evaluates the bioinformatics capabilities of European laboratories in analyzing viral genomic…

ABC's Dr. Tara Narula on Health Misinformation and Where to Turn

Health Misinformation and Trusted Medical Information: Insights from ABC’s Dr. Tara Narula This evidence dossier examines health misinformation issues discussed by Dr. Tara Narula, ABC News’ chief medical correspondent, in the podcast episode of “The Future of Medicine.” The episode aired in November 2026 and focuses on challenges around health misinformation, trust…

Analysis of antimicrobial resistance in the LAKANA trial of azithromycin administration in Mali: A sub-study of a cluster randomized clinical trial

Evidence Dossier: Azithromycin Mass Administration and Antimicrobial Resistance from the LAKANA Trial in Mali What is established Mass drug administration (MDA) of azithromycin has been trialed as a public health intervention to reduce under-five mortality in sub-Saharan Africa, with some studies showing mortality benefit especially when given to children aged 1 to…

Human medicines European public assessment report (EPAR): Ruxolitinib Krka, ruxolitinib, Status: Opinion

Health & Science Evidence Dossier: Ruxolitinib Krka What is established Ruxolitinib is a protein kinase inhibitor targeting Janus-associated kinases (JAKs), enzymes involved in signaling pathways important for blood cell production and immune regulation. The original branded version, Jakavi, has been authorized in the European Union since 2012 for several conditions, including myelofibrosis,…